Where is the bottom??, page-47

Quote from Keith Williams Seeking alpha on the trading halt:
I have to say that my timing is pretty interesting, as shortly after my article was published, Starpharma went into trading halt with the resulting announcement (see Aussie Machead's link below) being interpreted extremely negatively by the market.The announcement was that Astra Zeneca has decided to cease developing AZD0466 after a small number of asymptomatic adverse events. The context for this announcement is a quite massive program of new drug developments by Astra Zeneca. To get a sense of this see the Q2 2023 earnings call transcript from Astra Zeneca. seekingalpha.com/... The company is having amazing success with its clinical trials programs. They have plenty of really strong programs and this means any suspect program is under intense scrutiny.The point about AZD0466 is that this is a DEP-conjugate of a potential blockbuster Astra Zeneca drug AZD4320, which proved to be too toxic to take into the clinic. The coupling of AZD4320 with Starpharma's DEP hoped to overcome that toxicity and the results show that AZD0466 was looking good to have overcome the toxicity problems. The latest results have shown some toxicity and Astra Zeneca (with lots of promising new drugs under development) has pulled the plug on further work on AZD0466.So Starpharma's most advanced DEP program has been terminated, but this is not a result of DEP technology. The key point is that AZD0466 had largely resolved the toxicity problems but AZN decided that there was still risk.... and Astra Zeneca's multiproduct DEP license agreement remains in place.Another way of interpreting this latest news might be that the market is offering to brave investors a further 30% discount to Starpharma's share price as a result of Astra Zeneca having an amazing pipeline of new drugs under development.I have a full allocation of SPHRY shares in my portfolio, but I'm thinking that this is a rare opportunity worth thinking about more...
…………


It is probably very significant.

Also a PLUS for Starpharma value - dendrimer patents are held till 2032